MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 ...

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

Regeneron and ModeX Therapeutics have joined forces in a collaboration worth over one billion dollars to develop ...

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

ModeX Therapeutics enters research collaboration with Regeneron to develop multispecific antibodies for select therapeutic indications: Weston, Massachusetts Thursday, October 30, ...

Chris Planto has rejoined Rate as VP of mortgage lending in Houston after serving as a senior loan officer at CrossCountry ...

WESTON, Mass. - ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), with a market capitalization of $1.15 billion and current stock price of $1.45, has dosed the first patient in a Phase ...

Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive ...